Skip to main content

A private affair

With the take-over of Boots the Chemist raising the temperature on the high street, the debate about whether investment by private equity companies is a good prescription or an asset-stripper for British companies is back on people's lips, as Veronica Cowan reports

Recent news stories on the take-over of Boots the Chemist have bought the argument about the pros and cons of private equity investment to the fore in the insurance market.

Mergers and acquisitions can

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@postonline.co.uk or view our subscription options here: https://subscriptions.postonline.co.uk/subscribe

You are currently unable to copy this content. Please contact info@postonline.co.uk to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Insurance Post? View our subscription options

Q&A: James Rendell, BirdsEyeView

James Rendell, CEO and founder of BirdsEyeView, breaks down the gap he observed in the natural catastrophe and hazard modelling market that led to the launch of the business and his plans for its recent fundraise.

Managing the ‘forever risk’ of PFAS

How PFAS, often called “forever chemicals”, is creating one of the most complex and far-reaching environmental risks for insurers today is the topic of the latest Insurance Post Podcast.

Most read articles loading...

You need to sign in to use this feature. If you don’t have an Insurance Post account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here